270 related articles for article (PubMed ID: 26797318)
1. Caregiver Satisfaction with a Multisite Trial of Atomoxetine and Parent Training for Attention-Deficit/Hyperactivity Disorder and Behavioral Noncompliance in Children with Autism Spectrum Disorder.
Hollway JA; Aman MG; Mendoza-Burcham MI; Silverman L; Arnold LE; Tumuluru R; Handen BL; Lecavalier L; Page K; Sayre P; Smith T
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):807-814. PubMed ID: 26797318
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine and Parent Training for Children With Autism and Attention-Deficit/Hyperactivity Disorder: A 24-Week Extension Study.
Smith T; Aman MG; Arnold LE; Silverman LB; Lecavalier L; Hollway J; Tumuluru R; Hyman SL; Buchan-Page KA; Hellings J; Rice RR; Brown NV; Pan X; Handen BL
J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):868-876.e2. PubMed ID: 27663942
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
[TBL] [Abstract][Full Text] [Related]
4. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
5. Atomoxetine, Parent Training, and Their Effects on Sleep in Youth with Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
Hollway JA; Mendoza-Burcham M; Andridge R; Aman MG; Handen B; Arnold LE; Lecavalier L; Williams C; Silverman L; Smith T
J Child Adolesc Psychopharmacol; 2018 Mar; 28(2):130-135. PubMed ID: 29112459
[TBL] [Abstract][Full Text] [Related]
6. Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder.
Lecavalier L; Pan X; Smith T; Handen BL; Arnold LE; Silverman L; Tumuluru RV; Hollway J; Aman MG
J Autism Dev Disord; 2018 Apr; 48(4):980-987. PubMed ID: 29022125
[TBL] [Abstract][Full Text] [Related]
7. Adverse Events of Atomoxetine in a Double-Blind Placebo-Controlled Study in Children with Autism.
Tumuluru RV; Corbett-Dick P; Aman MG; Smith T; Arnold LE; Pan X; Buchan-Page KA; Brown NV; Ryan MM; Hyman SL; Hellings J; Williams C; Hollway JA; Lecavalier L; Rice RR; McAuliffe-Bellin S; Handen BL
J Child Adolesc Psychopharmacol; 2017 Oct; 27(8):708-714. PubMed ID: 28509573
[TBL] [Abstract][Full Text] [Related]
8. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
[TBL] [Abstract][Full Text] [Related]
9. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
10. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression.
Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
[TBL] [Abstract][Full Text] [Related]
12. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Harfterkamp M; van der Meer D; van der Loo-Neus G; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2015 May; 25(4):372-5. PubMed ID: 25919900
[No Abstract] [Full Text] [Related]
13. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
Lin HY; Gau SS
Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
[TBL] [Abstract][Full Text] [Related]
15. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
[TBL] [Abstract][Full Text] [Related]
16. Predictors of relapse or maintenance of response in pediatric and adult patients with attention-deficit/hyperactivity disorder following discontinuation of long-term treatment with atomoxetine.
Thome J; Dittmann RW; Greenhill LL; Lipsius S; Tanaka Y; Bushe C; Escobar R; Heinloth AN; Upadhyaya H
Atten Defic Hyperact Disord; 2017 Dec; 9(4):219-229. PubMed ID: 28477289
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
Walker DJ; Mason O; Clemow DB; Day KA
Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
[TBL] [Abstract][Full Text] [Related]
18. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
[TBL] [Abstract][Full Text] [Related]
19. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
Su Y; Yang L; Stein MA; Cao Q; Wang Y
J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of methylphenidate and atomoxetine on intrinsic brain activity in children with attention deficit hyperactivity disorder.
Shang CY; Yan CG; Lin HY; Tseng WY; Castellanos FX; Gau SS
Psychol Med; 2016 Nov; 46(15):3173-3185. PubMed ID: 27574878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]